



MIKA NISHIMURA

Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America. She has an exceptional track record of leading businesses from inception to across different clinical segments, including cardiovascular, fertility, and oncology.

Mika is an independent director of SI Bone (NASDAQ – SIBN), an orthopedic/spine implant company, Accuray (NASDAQ – ARAY), a radiation oncology equipment manufacturer, and HOYA (Tokyo Stock Exchange Prime: 7741), a diversified manufacturer of life science and IT products leveraging advanced optics technologies. In addition, she is also a board advisor to Tristel, plc, a UK public company, and a leader in high-level disinfection and decontamination technology.

Since 2011, Mika has been an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund with \$1.5B under management and currently investing out of Gilde V, a \$460M fund.

In her most recent operating role, Mika was Vice President, Commercialization at nVision Medical Corporation, an early clinical-stage company focused on early detection of ovarian cancer acquired by Boston Scientific for \$275M. Previously, Mika was Vice President, Commercial Development at Auxogyn, a company focused on reproductive health. Progyny, Inc acquired the company in 2015.

Earlier in her career, Mika was Vice President, International Sales Operations and Marketing at ev3 Inc., where she held P&L responsibilities for the emerging markets.

Mika has an MBA from Harvard Graduate School of Business Administration and a BA in Economics from Yale University.